12/11
12:29 pm
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.
12/11
12:29 pm
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.
12/11
12:22 pm
prld
Rating for PRLD
Low
Report
Rating for PRLD
12/11
12:22 pm
prld
Rating for PRLD
Low
Report
Rating for PRLD
11/8
12:31 pm
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
10/28
08:25 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.